Study summary

Enfortumab vedotin plus pembrolizumab nearly doubled survival as first treatment

EV-302 trial · Phase 3, randomized · Published March 2024, New England Journal of Medicine; FDA approved December 2023

+15.4 momedian survival: 31.5 vs 16.1 months

What was tested

Enfortumab vedotin, an antibody-drug conjugate, plus pembrolizumab, against platinum chemotherapy, as first treatment for advanced or metastatic bladder cancer.

What they found

Median survival was 31.5 months vs 16.1 with chemotherapy.
Tumors shrank in 68% vs 44%.

What it means

Replaced chemotherapy as the first treatment for most people with advanced bladder cancer.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.